1301606-98-3

Upstream product

• 18039-42-4 5-Phenyl-1H-tetrazole 
• 512182-38-6 1-(p-methoxybenzyl)-5-phenyl-1H-tetrazole 
• 21388-92-1 4-bromobenzyl acetate 
• 41882-10-4 N-(4-methoxybenzyl)benzamide 
• 98-88-4 benzoyl chloride 
• 2393-23-9 4-methoxy-benzylamine 
• 824-94-2 p-methoxybenzyl chloride 
• 873-75-6 4-bromobenzenemethanol 

Downstream Products

• 1307853-51-5 2-butyl-4-chloro-1-({2'-[1-(p-methoxybenzyl)-1H-tetrazol-5-yl]-biphenyl-4-yl}-methyl)imidazole-5-carbaldehyde 
• 1307853-52-6 2-butyl-4-chloro-1-({2'-[1-(p-methoxybenzyl)-1H-tetrazol-5-yl]-biphenyl-4-yl}-methyl)imidazole-5-methanol 
• 1307853-38-8 {2'-[1-(p-methoxybenzyl)-1H-tetrazol-5-yl]biphenyl-4-yl}-methanol 
• 1307853-40-2 5-[4'-(bromomethyl)biphenyl-2-yl]-1-(p-methoxybenzyl)-1H-tetrazole 
• 114798-36-6 2-n-Butyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole-5-carboxaldehyde 
• 114798-26-4 lorsartan 
• 145040-37-5 candesartan cilexetil 
• 676129-93-4 (S)-3-methyl-2-((2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl)-amino)-butyric acid benzyl ester 
• 1307853-55-9 benzyl N-({2'-[1-(p-methoxybenzyl)-1H-tetrazol-5-yl]biphenyl-4-yl}methyl)-L-valinate 
• 1307853-69-5 methyl 2-(N-tert-butoxycarbonyl-N-{(2'-[1-(p-methoxybenzyl)-1H-tetrazol-5-yl]biphenyl-4-yl)methyl}amino)-3-nitrobenzoate 
• 1307853-71-9 methyl 2-[({2'-[1-(p-methoxybenzyl)-1H-tetrazol-5-yl]biphenyl-4-yl}methyl)amino]-3-nitrobenzoate 
• 1307853-72-0 methyl 2-[({2'-[1-(p-methoxybenzyl)-1H-tetrazol-5-yl]biphenyl-4-yl}methyl)amino]-3-aminobenzoate 
• 1307853-73-1 C₃₃H₃₀N₆O₄ 
• 1307853-76-4 C₃₂H₂₈N₆O₄ 

Relevant academic research and scientific papers

PROCESS FOR PRODUCTION OF BIPHENYL DERIVATIVE

The invention provides a production method of a biaryltetrazole derivative useful as an intermediate for an angiotensin II receptor antagonist. The method comprises reacting an aryltetrazole derivative with a benzene derivative, deprotecting or reducing the resulting compound, and halogenating the deprotected or reduced compound

Synthesis of angiotensin II receptor blockers by means of a catalytic system for C-H Activation

A highly efficient catalytic system for C-H activation has been worked out that involves inexpensive RuCl3·xH2O and a specific amount of PPh3. This procedure has been successfully applied to a practical synthesis of angiotensin II receptor blockers (ARBs). The residual ruthenium that existed in the reaction mixture was thoroughly removed by treatment with properly selected metal scavengers. The new process permits ready access to the important class of drugs in a highly atom-economical and sustainable manner (Figure presented).